The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended updating the label for Alhemo® to include treatment for severe hemophilia A and B without inhibitors. This recommendation is based on positive results from the explorer8 trial, showing significant reductions in bleeds compared to no prophylaxis. If approved by the European Commission, Alhemo® could offer an easy-to-use option for patients with hemophilia A and B without inhibitors. Novo Nordisk expects approval within two months, pending EC review. Alhemo® is currently approved in several countries for routine prophylaxis in adolescents and adults with hemophilia A and B.

Read more at GlobeNewswire: European regulatory authority adopts positive opinion for